Nurix announces first clinical responses in brain for BTK degrader NX-5948

Nurix Therapeutics, Inc.

NX-5948 detected in CSF from all available samples, showing brain penetration.
CLL patient with CNS involvement achieved partial response by week 24 and cleared tumor cells from CSF.
PCNSL patient with MYC rearrangement had complete regression of three lesions at week 8, but progressed by week 16.
Data presented at AACR 2024; NX-5948 is an oral BTK degrader in Phase 1a/1b for B cell malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.